优化CT衰减与SUV阈值鉴别骨岛与转移瘤
回顾性分析117例患者169个病灶,评估CT衰减值和SUV在鉴别骨岛与未治疗及治疗后的成骨性转移瘤中的准确性。鉴别骨岛与未治疗转移瘤时,平均CT衰减AUC为90.8%(阈值795 HU),SUVmax AUC为94.9%(阈值2.2);鉴别骨岛与治疗后的转移瘤时各指标AUC下降,CT衰减最佳AUC为82.7%,联合模型AUC升至88.3%。
要点
- CT衰减和SUV可可靠鉴别骨岛与转移瘤。
- 鉴别治疗后转移瘤时准确性下降,CT衰减最佳AUC为82.7%。
- 联合CT衰减与SUV的模型AUC达88.3%,优于单独SUVmax或SUVmean。
核心结论
- CT衰减和SUV能可靠区分骨岛与转移瘤,但鉴别治疗后转移瘤时准确性降低,联合模型可提高准确性。
研究设计与样本
- 回顾性分析117例患者169个病灶的18F-FDG PET/CT,其中65例为骨岛,52例显示病灶从未治疗向治疗后的成骨性转移瘤转变。
主要发现
- 鉴别骨岛与未治疗成骨性转移瘤,平均CT衰减AUC为90.8%,优化阈值795 HU;SUVmax AUC为94.9%,优化阈值2.2。
- 鉴别骨岛与治疗后的成骨性转移瘤,各指标AUC均下降,平均CT衰减最佳AUC为82.7%。
关键数值与推荐
- 鉴别骨岛与未治疗转移瘤:平均CT衰减阈值795 HU(AUC 90.8%),SUVmax阈值2.2(AUC 94.9%)。
- 联合CT衰减和SUV的预测模型AUC为88.3%,显著优于单独SUVmax(P=0.029)或SUVmean(P=0.049)。
临床怎么用
- 在18F-FDG PET/CT的衰减校正CT上,可结合CT衰减值和SUV辅助鉴别骨岛与转移瘤,尤其对未治疗转移瘤准确性较高。
- 对治疗后的成骨性转移瘤,单独指标准确性有限,建议采用联合预测模型提高鉴别准确性。
局限性
- 回顾性研究,样本量有限,需进一步前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The objective of this study was to evaluate the accuracy of using CT attenuation and SUVs to differentiate enostoses from untreated and treated osteoblastic metastases on the attenuation-correction CT component of F-FDG PET/CTs. METHODS: We retrospectively reviewed F-FDG PET/CT studies of 117 patients (169 lesions), of which 65 had imaging of enostoses, and 52 had imaging showing the transition of lesions from untreated to treated osteoblastic metastases. We measured the mean CT attenuations and the SUVmax and SUVmean of each lesion. Receiver operating characteristic curve analyses were used to evaluate the accuracy of each metric in distinguishing enostoses from untreated and treated osteoblastic metastases. RESULTS: For differentiating enostoses from untreated osteoblastic metastases, mean CT attenuation achieved an area under the receiver operating characteristic curve (AUC) of 90.8%, with an optimized threshold of 795 HU. SUVmax achieved an AUC of 94.9%, with an optimized threshold of 2.2. For differentiating enostoses from treated osteoblastic metastases, the AUCs for every metric decreased, with mean CT attenuation being the best at 82.7%. A joint predictive model combining both CT attenuation and SUV increased the AUC to 88.3%, and performance was significantly better than SUVmax or SUVmean alone (P = 0.029 and P = 0.049, respectively). CONCLUSIONS: CT attenuation and SUV can reliably distinguish between enostoses and metastases on F-FDG PET/CT. However, the accuracy of these metrics decreases when used to differentiate enostoses from treated metastases. A joint prediction model combining CT attenuation with SUV can improve accuracy.
引用
- Lee HT, Pryma DA, Sebro R, et al. Optimized CT Attenuation and SUV Prediction Thresholds for Differentiating Enostoses From Untreated and Treated Metastases on Attenuation-Corrected 18F-FDG PET/CT. Clin Nucl Med. 2020. PMID: 31693615. doi:10.1097/RLU.0000000000002808
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。